Sep 21, 2025, 07:47
WFH: Hemophilia Innovations from Factor Therapy to Gene Therapy
World Federation of Hemophilia (WFH) shared on X:
”Hemophilia has led rare disease innovation—from factor therapy to Gene Therapy—thanks to decades of advocacy and investment. But continued progress depends on sustained support. The future of treatment access is in our hands.
Read more in Blood Advances:”
Find similar posts on Hemostasis Today.
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number
-
Oct 9, 2026, 08:28Ghanim Fajish: Vascular Cells May Retain a Prothrombotic Memory of Oxidative Stress
-
Oct 9, 2026, 07:43Mehmet Cilingiroglu: The First Diagnosis of Coronary Thrombosis in a Living Patient
-
Oct 9, 2026, 07:21Federico Ravaioli: 40 kPa Spleen Stiffness May Help Avoid Endoscopy in Chronic PVT
-
Oct 9, 2026, 07:00Danny Reardon: Closing the Global Awareness Gap on Blood Clots
-
Oct 9, 2026, 00:54Mary Catherine Moffett: Advancing Advocacy Together – Highlights from the Sanofi Bleeding Disorders Summit